Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m

Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance

AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer

Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer

BioNTech completes acquisition of CureVac

BiBBInstruments reports additional US orders during targeted EndoDrill GI launch

Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients

Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic

RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL

Genmab completes tender offer for Merus and opens subsequent offering period

NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment

Anixa Biosciences reveals final data from Phase one clinical trial of investigational breast cancer vaccine at 2025 San Antonio Breast Cancer Symposium

Privo Technologies doses first patient in first-in-human clinical trial of PRV131

Senhwa Biosciences signs clinical supply agreement with BeOne Medicines

D3 Bio completes USD108m Series B financing round